A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Abstract Text:

Cari J McDonald,Charles Erlichman,James N Ingle,Gabriela A Rosales,Cory Allen,Suzanne M Greiner,Mary E Harvey,Paula J Zollman,Stephen J Russell,Evanthia Galanis,

Breast cancer is the most common malignancy and the second leading cause of female cancer mortality in the United States. There is an urgent need for development of novel therapeutic approaches. In this study, we investigated the antitumor potential of a novel viral agent, an attenuated strain of measles virus deriving from the Edmonston vaccine lineage, genetically engineered to produce carcinoembryonic antigen (CEA) against breast cancer. CEA production as the virus replicates can serve as a marker of viral gene expression. Infection of a variety of breast cancer cell lines including MDA-MB-231, MCF7 and SkBr3 at different multiplicities of infection (MOIs) from 0.1 to 10 resulted in significant cytopathic effect consisting of extensive syncytia formation and massive cell death at 72-96 h from infection. All breast cancer lines overexpressed the measles virus receptor CD46 and supported robust viral replication, which correlated with CEA production. TUNEL assays indicated an apoptotic mechanism of syncytial death. The efficacy of this approach in vivo was examined in a subcutaneous Balb C/nude mouse model of MDA-MB-231 cells. Intravenous administration of MV-CEA at a total dose of 1.2 x 10(7) TCID50 resulted in statistically significant tumor growth delay ( p=0.005) and prolongation of survival ( p=0.001). In summary, MV-CEA has potent antitumor activity against breast cancer lines and xenografts. Monitoring marker peptide levels in the serum could serve as a low-risk method of detecting viral gene expression during treatment and could allow dose optimization and individualization of treatment. Trackable measles virus derivatives merit further exploration in breast cancer treatment.

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Publishing Authors By Initials

CJ McDonald,C Erlichman,JN Ingle,GA Rosales,C Allen,SM Greiner,ME Harvey,PJ Zollman,SJ Russell,E Galanis,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Breast cancer research and treatment

VOLUME: 99

Page Numbers: 177-84

Journal Abbreviation:

ISSN: 0167-6806

DAY: 27

MONTH: 04

YEAR: 2006

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8111104

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.

AFFILIATION: Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Breast Cancer Res Treat

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer Related Publications

• A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
• Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
• Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
• Evaluation of the surveillance of Hemolytic Uremic Syndrome in British Columbia: should it remain reportable?
• Heat shock protein inhibitors increase the efficacy of measles virotherapy.
• High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
• Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
• Oncolytic measles virus strains in the treatment of gliomas.
• Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
• Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
• Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.